CRISPR-Cas9-modified <em>pfmdr1</em> protects <em>Plasmodium falciparum </em>asexual blood stages and gametocytes against a class of... (Publications)
Emerging resistance to first-line antimalarial combination therapies threatens malaria treatment and the global elimination campaign. Improved therapeutic strategies are required to protect existing d
Antibody-mediated neutralization of the exotoxin mycolactone, the main virulence factor produced by <em>Mycobacterium ulcerans</em> (Publications)
BACKGROUND: Mycolactone, the macrolide exotoxin produced by Mycobacterium ulcerans, causes extensive tissue destruction by inducing apoptosis of host cells. In this study, we aimed at the production o
Non-vector-borne transmission of Zika virus: a systematic review (Publications)
BACKGROUND: Increasing numbers of confirmed cases of Zika virus (ZIKV) infection resulting from non-mosquito-borne transmission have been reported. METHODS: We performed a systematic literature review
Single ascending dose pharmacokinetic study of tribendimidine in <em>Opisthorchis viverrini</em>-infected patients (Publications)
OBJECTIVES: Praziquantel is the only drug available for treatment of Opisthorchis viverrini infections. Tribendimidine has emerged as potential treatment alternative, however its pharmacokinetic (PK)
Induction of humoral immune response to multiple recombinant <em>Rhipicephalus appendiculatus</em> antigens and their effect on tick feeding success... (Publications)
BACKGROUND: Rhipicephalus appendiculatus is the primary vector of Theileria parva, the etiological agent of East Coast fever (ECF), a devastating disease of cattle in sub-Saharan Africa. We hypothesiz
Host-directed therapies for infectious diseases: current status, recent progress, and future prospects (Publications)
Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functional disability arising from
Population pharmacokinetic modeling of tribendimidine metabolites in <em>Opisthorchis viverrini</em>-infected adults (Publications)
There is a pressing need for alternative treatments against the liver fluke Opisthorchis viverrini Oral tribendimidine is a promising candidate, but its population pharmacokinetic properties are unkno